Information and control
This article was originally published in Scrip
The European Commission has put out its proposals for a regulation on public information on prescription drugs. Essentially designed to stop direct to consumer advertising, the regulation creates an editorial office at the European Medicines Agency at a cost of some €3 million a year that will examine written or electronic materials that companies want to put out on their drugs. There will be additional costs at the national regulators, too. All costs, of course, will be covered by companies but ultimately passed on to healthcare payers.
You may also be interested in...
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.
Celgene agrees to pay $75m upfront for options to three Immatics TCR-T targets for solid tumors. Deal could be worth up to $1.59bn to the German biotech, which also retains option to co-develop and co-fund certain licensed products.